-

Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement

WHIPPANY, N.J.--(BUSINESS WIRE)--Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a campaign focused on helping people better understand and relieve 7 common PMS symptoms – period cramps, bloating, fatigue, backaches, muscle aches, headaches, and water retention – through a combination of symptom relief and supportive movement.

Midol® in Motion is grounded on consumer experience and research:

  • Period symptoms can interrupt movement and daily routines, making it harder to stay active. Research shows that 55% and 61% of women change their training schedules due to menstrual and premenstrual symptoms, respectively, and nearly two in five women skip workouts altogether during their period.2,3
  • Exercise is a powerful tool for easing PMS pain, fatigue, and other disruptive symptoms.
  • When paired with Midol® Complete’s multi‑symptom* relief, Midol® in Motion highlights how people can stay active and maintain their routines. *Relief of period cramps, bloating, fatigue, backaches, muscle aches, headaches, and water retention.

As part of the campaign, Midol® will be hosting an immersive afternoon of movement and education designed to help people better understand and relieve PMS symptoms. The experience will include live workouts led by Midol® partner and Barre Certified fitness influencer and instructor, Jenna Palek, as well as Midol® partner and NASM and Barre certified fitness influencer and instructor, Makena Rae Diehl, focusing on ways of movement to target and help alleviate different period symptoms. The afternoon will also include interactive stations highlighting different solutions to help relieve common PMS symptoms, so they don’t get in the way of daily routines.

Beyond the live event, the Midol® in Motion campaign extends across a broader digital and social ecosystem, bringing the movement to life through ongoing content across Midol®'s owned and partner channels. This includes a series of original social content highlighting expert guidance, intentional movement routines, and practical ways to help manage common PMS symptoms as a part of everyday life. Through creator partnerships and educational storytelling, the campaign aims to show how people can stay on track with their routines during their period.

Midol® in Motion focuses on helping people reclaim their physical comfort and daily routines during their period,” said Lisa Perez, Bayer General Manager of PCD and Nutritionals. “By pairing symptom relief from Midol® Complete with supportive movement, we’re helping menstruators address multiple PMS symptoms that can get in the way of everyday activities. Period symptoms can make people feel unlike themselves. Our goal is to help them address those period symptoms so they can stay connected to the movement and routines that help them feel like themselves again.”

Midol® in Motion will highlight intentional movement modalities shown to help support the body during the menstrual cycle, including:

  • Aerobic + cardio: Light cardio such as walking, jogging, or biking to help ease bloating and water retention
  • Yoga + Pilates: Core focused exercises and continuous movement designed to help relieve cramps, backache, and muscle aches
  • Meditation + Stretching: Slow, intentional movements help menstruators with headaches and fatigue.

“Periods can make movement feel harder than it should, and I know firsthand how easy it is to cancel workouts when fatigue or bloating hits,” explains Midol® partner and fitness influencer Jenna Palek. “Midol® in Motion is about choosing intentional movement that supports how you physically feel. When I pair comfort‑first movement with Midol® Complete (as directed), I’m able to relieve multiple PMS symptoms* to get back to feeling like myself.”

*period cramps, bloating, fatigue, backaches, muscle aches, headaches, and water retention

Follow the movement via the Midol® social channels, @Midol on Instagram and TikTok.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

References:

1. Li H, Sarokhani M, Gilan MHS, Valizade R, Sayehmiri K. Prediction premenstrual syndrome (PMS) with anxiety, and depression in female students. BMC Psychiatry. 2025 Aug 18;25(1):794. doi: 10.1186/s12888-025-07250-z. PMID: 40826390; PMCID: PMC12359940.

2. Prado RCR, Willett HN, Takito MY, Hackney AC. Impact of Premenstrual Syndrome Symptoms on Sport Routines in Nonelite Athlete Participants of Summer Olympic Sports. Int J Sports Physiol Perform. 2022 Dec 28;18(2):142-147. doi: 10.1123/ijspp.2022-0218. PMID: 36577421.

3. Mahina. Beyond Blood: The Unseen Burden of Every Cycle. Mahina; 2025 May 28. Available from: https://mahina.co/pages/beyond-blood-report

Contacts

For U.S. media inquiries:
Christin Miller
Director of Integrated Strategic Communications
Email: christin.miller@bayer.com

Bayer

GER:BAYN

Release Versions

Contacts

For U.S. media inquiries:
Christin Miller
Director of Integrated Strategic Communications
Email: christin.miller@bayer.com

More News From Bayer

Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America, with Bayer donating 1 million meals* through Feeding America®. The campaign kicks off May 14–16 in California with a Walmart community food drive in Clovis, followed by additional food collection at Farm Tour stops in Clovis and Elk Grove. In partnership with Central California Food Bank and Sacr...

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evuzamitide.1,5 The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of...

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic R...
Back to Newsroom